BioCentury
ARTICLE | Company News

Cour Pharmaceutical, Takeda deal

January 18, 2016 8:00 AM UTC

Cour partnered with Takeda to develop and commercialize therapies for celiac disease and other gastrointestinal diseases using Cour’s Tolerizing Immune Modifying nanoParticle (TIMP) platform. TIMP therapy consists of encapsulated antigenic proteins and a polymer. The platform was developed in cooperation with Northwestern University (Evanston, Ill.). Takeda will have an exclusive option to globally license TIMP/Gliadin after completion of a Phase IIa trial and an option to collaborate on up to three additional TIMP compounds. TIMP/Gliadin is gliadin delivered using the TIMP platform. ...